Clinical use of vorapaxar as an emerging antithrombin agent: A literature review of current evidence
In response to the high prevalence of atherothrombotic diseases and the residual risks left by the current antiplatelet therapies, the Food and Drug Administration approved the use of vorapaxar as a secondary prevention of cardiovascular events. Vorapaxar is a novel oral antiplatelet agent that anta...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Journal of Applied Hematology |
| Subjects: | |
| Online Access: | http://www.jahjournal.org/article.asp?issn=1658-5127;year=2017;volume=8;issue=4;spage=127;epage=134;aulast=Algahtani |